Nanoparticle-based drug delivery systems to overcome gastric cancer drug resistance

被引:41
作者
Nejati, Kazem [1 ]
Rastegar, Mojgan [2 ]
Fathi, Farzaneh [1 ]
Dadashpour, Mehdi [3 ]
Arabzadeh, AmirAhmad [4 ]
机构
[1] Ardabil Univ Med Sci, Pharmaceut Sci Res Ctr, Ardebil, Iran
[2] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Biochem & Med Genet, Winnipeg, MB, Canada
[3] Semnan Univ Med Sci, Dept Med Biotechnol, Semnan, Iran
[4] Ardabil Univ Med Sci, Sch Med, Dept Surg, Ardebil, Iran
关键词
Gastric cancer; Chemotherapy; Nano-delivery systems; Multi-drug resistance; Chemoresistance; MESOPOROUS SILICA NANOPARTICLES; GLUTATHIONE S-TRANSFERASES; SOLID LIPID NANOPARTICLES; MULTIDRUG-RESISTANCE; POLYMERIC MICELLES; CARBON NANOTUBES; CO-DELIVERY; GOLD NANOPARTICLES; ANTICANCER DRUGS; TOPOISOMERASE-II;
D O I
10.1016/j.jddst.2022.103231
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gastric cancer (GC) results from deregulated cell growth in the stomach. Despite significant efforts and recent advancements in the treatment of gastric cancer, it remains a life-threatening disease. This is in part due to the chemotherapy failure resulting from multi-drug resistance (MDR) in the associated Gastric cancer cells (GCC). These cells can acquire MDR through different mechanisms. Perhaps the most important mechanism would be the increased drug efflux by ATP-binding cassette (ABC) transporters, which reduces the intracellular concentration of the chemotherapy drugs. Recently, nanoparticle-based drug delivery systems (nano-DDS) have been emerged to reverse MDR by altering the mechanisms through which the drugs may function. Nano-DDSs are also highly regarded because of their potential to enhance the pharmacological profile of chemotherapy drugs, improving drug solubility, and decrease their adverse effects. This review summarizes known factors that are involved in the MDR of GCC. Additionally, we will describe the application of nano-DDSs to reverse MDR in GCC.
引用
收藏
页数:10
相关论文
共 166 条
[1]   PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy [J].
Abedi-Gaballu, Fereydoon ;
Dehghan, Gholamreza ;
Ghaffari, Maryam ;
Yekta, Reza ;
Abbaspour-Ravasjani, Soheil ;
Baradaran, Behzad ;
Dolatabadi, Jafar Ezzati Nazhad ;
Hamblin, Michael R. .
APPLIED MATERIALS TODAY, 2018, 12 :177-190
[2]   Potential activity of free and PLGA/PEG nanoencapsulated nasturtium officinale extract in inducing cytotoxicity and apoptosis in human lung carcinoma A549 cells [J].
Adlravan, Elham ;
jalilzadeh-Razin, Sepideh ;
Nejati, Kazem ;
Karimi, Mohammad Ali ;
Mousazadeh, Hanieh ;
Abbasi, Akbar ;
Dadashpour, Mehdi .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2021, 61
[3]   Differential metabolic responses to pluronic in MDR and non-MDR cells: A novel pathway for chemosensitization of drug resistant cancers [J].
Alakhova, Daria Yu. ;
Rapoport, Nataliya Y. ;
Batrakova, Elena V. ;
Timoshin, Alexander A. ;
Li, Shu ;
Nicholls, David ;
Alakhov, Valery Yu. ;
Kabanov, Alexander V. .
JOURNAL OF CONTROLLED RELEASE, 2010, 142 (01) :89-100
[4]   Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases [J].
Allocati, Nerino ;
Masulli, Michele ;
Di Ilio, Carmine ;
Federici, Luca .
ONCOGENESIS, 2018, 7
[5]   Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer [J].
Alven, Sibusiso ;
Nqoro, Xhamla ;
Buyana, Buhle ;
Aderibigbe, Blessing A. .
PHARMACEUTICS, 2020, 12 (05)
[6]  
Arias JL, 2011, CURR DRUG TARGETS, V12, P1151
[7]   Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer [J].
Atmaca, Akin ;
Pauligk, Claudia ;
Steinmetz, Kristina ;
Altmannsberger, Hans-Michael ;
Jaeger, Elke ;
Al-Batran, Salah-Eddin .
ONCOLOGY, 2011, 80 (1-2) :130-134
[8]   TiO2 nanoparticles enhance the chemotherapeutic effects of 5-fluorouracil in human AGS gastric cancer cells via autophagy blockade [J].
Azimee, Shiva ;
Rahmati, Marveh ;
Fahimi, Hossein ;
Moosavi, Mohammad Amin .
LIFE SCIENCES, 2020, 248
[9]   Nanoparticles and targeted drug delivery in cancer therapy [J].
Bahrami, Behdokht ;
Hojjat-Farsangi, Mohammad ;
Mohammadi, Hamed ;
Anvari, Enayat ;
Ghalamfarsa, Ghasem ;
Yousefi, Mehdi ;
Jadidi-Niaragh, Farhad .
IMMUNOLOGY LETTERS, 2017, 190 :64-83
[10]  
Bar-Zeev M., 2018, J MOL CLIN MED, V1, P55